KKKarim G. Kheniser

Karim G. Kheniser

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karim G. Kheniser has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prevalence of Anemia in Subjects Randomized into Roux-en-Y Gastric Bypass or Sleeve Gastrectomy

    by Karim G. Kheniser, Sangeeta R. Kashyap, Philip R. Schauer, Eddie T. C. Lam, Emily S. Kullman

    Purpose Although bariatric surgery fosters heightened excess weight loss values, nutritional deficiencies are prominent; one of the most common being iron deficiency anemia. The purpose is to elucidate the frequency of anemia in Roux-en-Y gastric bypass and sleeve gastrectomy subjects. Materials and Methods A retrospective analysis was conducted, in subjects (N = 100) diagnosed with type II diabetes who were randomized into sleeve gastrectomy or Roux-en-Y gastric bypass and intensive medical therapy. Results Anemia was more common in female subjects who underwent sleeve gastrectomy—roughly half developed microcytosis at 24 months and thereafter. Conclusion The etiology of anemia appears to be iron-related and precipitated by the female sex. Scant iron supplementation is likely causative. However, anemia of chronic inflammation cannot be discounted as being somewhat causal. Subsequently, the aggregate may have had a synergistic influence.


  • Open Access

    The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes

    by Sangeeta Kashyap, Karim Kheniser, Ling Li, James Bena, Takhar Kasumov

    To determine whether 12 months of intensive medical therapy (IMT) improves HDL functionality parameters in subjects with type II diabetes (T2D). Retrospective, randomized, and controlled 12-month IMT intervention trial that enrolled 13-subjects with T2D (age 51- years, fasting glucose 147 mg/dL, body mass index [BMI] 36.5 kg/m2) and nine healthy control (46-years, fasting glucose 90 mg/dL, BMI 26.5 kg/m2). Subjects with T2D underwent IMT and HDL functionality measures (pro-inflammatory index of high-density lipoprotein (pHDL)), paraoxonase one (PON1), ceruloplasmin (Cp), and myeloperoxidase (MPO) activity were performed on samples at baseline and at 12-months following IMT. At baseline, pHDL index was significantly higher in subjects with T2D (p < 0.001) and apolipoprotein A-1 levels were significantly lower (p = 0.013) vs. controls. After 12-months, there was a trend for improved pHDL activity (p = 0.083), as indicated by intent-to-treat analysis, but when the non-adherent subject was omitted (per-protocol), significant attenuations in pHDL activity (p = 0.040) were noted; Δ pHDL activity at 12-months was associated with Δ weight (r = 0.62, p = 0.032) and Δ fasting glucose (r = 0.65, p = 0.022). Moreover, PON1 activity significantly improved (p < 0.001). The aforementioned occurred in association with improvements in inflammatory markers (i.e., C-reactive protein & tumor necrosis factor), hemoglobin A1C, fasting glucose, triglycerides, high-density lipoprotein levels and adipokines. IMT ameliorates pHDL index and significantly improves anti-oxidative function, as measured by PON1. Improvements in weight and fasting glucose mediated the decrease in pHDL index. Pharmacological aids and lifestyle modification are required to improve cardiovascular risk factors, subsequent mortality risk, and promote T2D remission. Application of either form of therapy alone may only have relatively miniscule effects on the aforementioned factors, in relation to the aggregate.